CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease
Sangmo Hong, Woo Je Lee, Cheol-Young Park
Endocrinol Metab. 2022;37(2):233-242.   Published online April 6, 2022
DOI: https://doi.org/10.3803/EnM.2021.1353

Excel Download

Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease
Endocrinology and Metabolism. 2022;37(2):233-242   Crossref logo
Link1 Link2 Link3

Effect of aspirin versus cilostazol for inhibition of antiplatelet aggregation in type 2 diabetes mellitus patients (ESCORT-DM Study)
. 2020;   Crossref logo
Link1 Link2

Aspirin and Other Antiplatelet Agents and Their Effects on Cardiovascular Disease in Type 2 Diabetes
Current Cardiovascular Risk Reports. 2011;6(1):62-70   Crossref logo
Link1 Link2 Link3

Lumiracoxib Does Not Affect the Ex Vivo Antiplatelet Aggregation Activity of Low-Dose Aspirin in Healthy Subjects
The Journal of Clinical Pharmacology. 2005;45(10):1172-1178   Crossref logo
Link1 Link2

Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study
Pharmacoepidemiology and Drug Safety. 2009;18(12):1143-1149   Crossref logo
Link1 Link2 Link3

CRT-225 Outside Start Cilostazol Bridge Study (Outpatient peri-Surgical Interruption of Drug Eluting Stent Antiplatelet Regimen Testing A Cilostazol Bridge Study): A 6 year experience
JACC: Cardiovascular Interventions. 2015;8(2):S2   Crossref logo
Link1 Link2

Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: Impact of high on-treatment platelet reactivity and diabetes mellitus status
Catheterization and Cardiovascular Interventions. 2012;81(1):42-49   Crossref logo
Link1 Link2

Combination antiplatelet therapy in patients with peripheral arterial disease: Is the best therapy aspirin, clopidogrel, or both?
Catheterization and Cardiovascular Interventions. 2009;74(S1):S1-S6   Crossref logo
Link1 Link2

P1929A randomized controlled trial evaluating outcome impact of cilostazol in patients with coronary artery disease and at a high risk of cardiovascular disease
European Heart Journal. 2019;40(Supplement_1):   Crossref logo
Link1 Link2

The Effects of Cardiovascular Risk Factor Combined Antiplatelet Therapy and the Risk of Cerebrovascular Events in Patients with T2DM in an Urban Community over 96-Month Follow-Up—The Beijing Communities Diabetes Study 19
Diabetes. 2018;67(Supplement_1):   Crossref logo
Link1 Link2